Best mid-cap healthcare stocks to invest in Q3 2024

The healthcare sector is a constant hive of innovation, relentlessly pushing the boundaries of treatment and technology. Mid-cap healthcare stocks offer an exciting chance to invest in the future of health, where established players stand poised for significant growth.

Intra-Cellular Therapies leads the way in novel central nervous system treatments. Diversified healthcare companies like Chemed Corp. boast a strong presence in medical equipment and home healthcare solutions. Bruker Corporation, a scientific instrument manufacturer, plays a crucial role in research and development across the healthcare sector. This selection showcases the diverse opportunities within the mid-cap healthcare landscape.

Curious how these leading mid-cap healthcare companies can impact your portfolio? Dive deeper with us for insightful analysis to inform your investment decisions and build a robust, healthcare-focused portfolio positioned for a thriving Q3 2024.

Roboforex R-Trader gives you access to over 10,000 stocks, ETFs, commodities, and crypto. All of the stocks mentioned in this article are available for purchase there.

Before we dive into each company, let`s take a look at how your investment would have performed if you had invested in top 10 stocks mentioned in this article 5 years ago.

Now, let`s take a closer look at each of the companies:

  • Intra-Cellular Therapies (ITCI)

    Intra-Cellular Therapies (ITCI) isn't your typical pharmaceutical company. Forget mass-produced drugs for common ailments. Intra-Cellular sets its sights on a more complex target – the intricate workings of the human brain. This biopharmaceutical company focuses on developing innovative treatments for neuropsychiatric and neurological disorders, aiming to improve the lives of millions struggling with these often-debilitating conditions. But can Intra-Cellular Therapies translate its groundbreaking research and focus on central nervous system (CNS) diseases into rewarding returns for your investment portfolio? Let's delve into the science behind the treatments and explore the forces propelling Intra-Cellular's journey, while acknowledging the potential hurdles to consider before joining this medical innovation expedition.

    Intra-Cellular Therapies financial statements

    Analysts recommendation: 1.41

    Financial Health

    • Return on assets (ROA): -15.09%
    • Return on equity (ROE): -18.07%
    • Return on investment (ROI): -18.11%

    Profitability

    • Gross margin: 92.82%
    • Operating margin: -25.67%
    • Net profit margin: -21.57%

    Growth

    • EPS (past 5 years): 12.47%
    • EPS (current): -1.15
    • EPS estimate (next quarter): -0.19
    • EPS growth (this year): 63.56%
    • EPS growth (next year): 303.83%
    • EPS growth (next 5 years): N/A
    • EPS growth (quarter-over-quarter): 66.01%
    • Sales growth (past 5 years): 7617.73%
    • Sales growth (quarter-over-quarter): 52%

    💡 Why invest in Intra-Cellular Therapies?

    Several key factors make Intra-Cellular an intriguing prospect for investors seeking exposure to the burgeoning field of CNS therapies:

    • Novel Drug Development Approach: Intra-Cellular leverages a Nobel Prize-winning research platform to design small molecule drugs. This approach differs from traditional therapies, potentially leading to more targeted and effective treatments.
    • Focus on Unmet Medical Needs: Intra-Cellular prioritizes developing treatments for diseases with limited therapeutic options. This focus on unmet medical needs positions the company to address critical gaps in patient care.
    • Diversified Pipeline: Intra-Cellular boasts a pipeline of potential drug candidates at various stages of development, targeting a range of CNS disorders like schizophrenia, bipolar disorder, and depression. This diversification mitigates risk by offering multiple growth prospects.
    • Experienced Leadership: The company is led by a team of seasoned scientists and industry veterans, bringing a wealth of expertise to drug development and navigating the complexities of the pharmaceutical industry.

    🐌 Key considerations before investing in Intra-Cellular Therapies

    While Intra-Cellular strives to unlock the brain's potential with its innovative therapies and focus on unmet medical needs, some challenges remain before joining this medical innovation expedition:

    • High-Risk, High-Reward: Developing CNS therapies is inherently risky. Clinical trials can be lengthy, expensive, and have an uncertain outcome. Investors should have a high-risk tolerance for this sector.
    • Regulatory Hurdles: Gaining regulatory approval for new drugs from agencies like the FDA is a complex and time-consuming process. Delays or setbacks in the approval process can significantly impact timelines and company value.
    • Competition Heats Up: The CNS therapy landscape is becoming increasingly competitive, with established players and emerging companies vying for market share. Staying informed about industry trends and Intra-Cellular's strategies for differentiation is crucial.
    • Focus on Early-Stage Development: A significant portion of Intra-Cellular's pipeline is in the early stages of development. The success of these therapies remains uncertain, requiring careful consideration of the company's risk profile.

    Final thoughts on Intra-Cellular Therapies

    Intra-Cellular Therapies' commitment to pioneering CNS therapies, focus on unmet medical needs, and diversified pipeline paint a potentially promising picture for long-term investors seeking exposure to the evolving field of neurological treatments. However, the high-risk nature of drug development, regulatory hurdles, rising competition, and early-stage pipeline necessitate a cautious approach. Thorough research, analysis of Intra-Cellular's clinical trials progress, regulatory landscape, and competitive environment, and a clear understanding of your risk tolerance are crucial before joining this medical innovation expedition. Remember, navigating the intricate terrain of CNS therapy stocks requires a discerning eye for scientific advancements, regulatory developments, and a balanced perspective on potential challenges. Choose wisely, and your portfolio might just find itself unlocking new possibilities alongside the success story of Intra-Cellular Therapies.

  • UFP Technologies (UFPT)

    In the ever-evolving landscape of manufacturing and packaging, where innovation defines success and precision meets diverse needs, UFP Technologies steps into the spotlight. This designer and custom manufacturer isn't just shaping foam, plastics, and films; it's orchestrating a symphony of engineering expertise, catering to industries ranging from medical devices to aerospace. But can this material maestro translate its shaping skills into rewarding returns for your portfolio? Let's explore the hidden complexities propelling UFP's rise, alongside the potential challenges to consider before joining this manufacturing odyssey.

    UFP Technologies financial statements

    Analysts recommendation: 1.67

    Financial Health

    • Return on assets (ROA): 11.99%
    • Return on equity (ROE): 17.68%
    • Return on investment (ROI): 14.29%

    Profitability

    • Gross margin: 27.89%
    • Operating margin: 15.17%
    • Net profit margin: 11.75%

    Growth

    • EPS (past 5 years): 24.81%
    • EPS (current): 6.21
    • EPS estimate (next quarter): 1.54
    • EPS growth (this year): 11.15%
    • EPS growth (next year): 14.68%
    • EPS growth (next 5 years): N/A
    • EPS growth (quarter-over-quarter): 29.4%
    • Sales growth (past 5 years): 18.83%
    • Sales growth (quarter-over-quarter): 7.42%

    💡 Why invest in UFP Technologies?

    UFP Technologies' robust profile makes it a tempting pick for investors seeking exposure to the dynamic manufacturing and packaging sectors. Here's what fuels its diverse material mastery:

    • Material Mastery: UFP boasts expertise in diverse materials like foams, plastics, and films, utilizing advanced techniques like laminating, molding, and fabrication to create custom solutions across various industries. This material know-how translates into a wide range of offerings and a strong foundation for growth.
    • Beyond Medical Devices: Recognizing the diverse needs of its clients, UFP expands its focus beyond medical devices, offering engineered components and packaging solutions to industries like aerospace, automotive, consumer goods, and electronics. This strategic diversification mitigates risk and unlocks diverse avenues for growth.
    • Innovation Engine: UFP prioritizes research and development, investing in advanced technologies and materials to create innovative solutions for evolving customer needs. This commitment to innovation positions the company for future success in a rapidly changing landscape.
    • Global Reach: With operations spanning the US, Mexico, and Europe, UFP caters to diverse client needs worldwide. This global reach provides access to emerging markets and further bolsters its future prospects.

    🐌 Key considerations before investing in UFP Technologies

    While UFP navigates the manufacturing labyrinth with its material expertise and global reach, there are some potential hurdles to consider before joining this high-stakes journey:

    • Valuation Concerns: Like many industrials, UFPT's stock can be volatile, reflecting expectations of future raw material prices, economic conditions, and overall market sentiment. A cautious approach with a patient, long-term perspective is wise.
    • Competition Heats Up: Smaller regional manufacturers and global conglomerates are vying for market share, challenging UFP's dominant position. Stay informed about industry trends and how UFP plans to maintain its competitive edge.
    • Economic Jitters: Global economic downturns can impact industrial spending and project development, potentially hitting UFP's sales and profitability. Close monitoring of economic trends and their impact on manufacturing is crucial.
    • Regulatory Landscape: Evolving regulations surrounding materials, environmental impact, and product safety can impact UFP's operations and necessitate costly compliance measures. Monitoring regulatory developments and UFP's adaptation strategies is important.

    Final thoughts on UFP Technologies

    UFP Technologies' diverse material expertise, focus on innovation, global reach, and diversified client base paint a potentially promising picture for long-term investors seeking exposure to the dynamic manufacturing and packaging sectors. However, the volatile nature of the stock, rising competition, economic sensitivity, and evolving regulatory landscape warrant a measured approach. Thorough research, analysis of UFP's future plans and the manufacturing landscape, and a clear understanding of your risk tolerance are crucial before joining this manufacturing expedition. Remember, navigating the intricate terrain of industrial stocks requires both a discerning eye for innovative solutions and a balanced perspective on potential challenges. Choose wisely, and your portfolio might just find itself custom-crafted for success alongside UFP Technologies.

  • Ensign Group (ENSG)

    Ensign Group might not be a common name at the grocery store, but within the senior living industry, they're a dominant force. Forget about the outdated image of sterile nursing homes, The Ensign Group specializes in creating vibrant communities that offer a range of care services for seniors. Imagine them as the architects of active aging, providing supportive environments that promote well-being, independence, and social connection. Their services cater to a growing demographic of aging baby boomers, offering valuable solutions for families seeking quality senior care. Their dedication to innovative care models and a focus on regional expansion positions them as a key player in the evolving senior living landscape.

    Ensign Group financial statements

    Analysts recommendation: 1.67

    Financial Health

    • Return on assets (ROA): 5.35%
    • Return on equity (ROE): 15.08%
    • Return on investment (ROI): 6.38%

    Profitability

    • Gross margin: 12.29%
    • Operating margin: 5.21%
    • Net profit margin: 5.77%

    Growth

    • EPS (past 5 years): 16.56%
    • EPS (current): 3.8
    • EPS estimate (next quarter): 1.3
    • EPS growth (this year): 13.22%
    • EPS growth (next year): 10.33%
    • EPS growth (next 5 years): 15%
    • EPS growth (quarter-over-quarter): 13.38%
    • Sales growth (past 5 years): 15.98%
    • Sales growth (quarter-over-quarter): 14.23%

    💡 Why invest in Ensign Group?

    The Ensign Group's unique position in the skilled nursing and senior living market offers several potential advantages for investors seeking exposure to this growing sector:

    • High-Growth Market: The aging population is driving a significant demand for senior living services, creating a favorable market environment for The Ensign Group.
    • Focus on Quality Care: They prioritize resident well-being and offer a range of care options, including skilled nursing, rehabilitation, and assisted living services.
    • Acquisition-Driven Growth Strategy: The Ensign Group actively acquires and integrates new facilities, allowing for rapid expansion and market share growth.
    • Focus on Operational Efficiency: They prioritize efficient management practices, potentially leading to improved profitability and returns.

    🐌 Key considerations before investing in Ensign Group

    However, before investing in The Ensign Group, it's crucial to consider the potential challenges:

    • Regulatory Environment: The senior living industry is heavily regulated, and changes in regulations could impact operational costs and profitability.
    • Reimbursement Rates: Reimbursement rates from government programs like Medicare and Medicaid can be a significant source of revenue, and changes in these rates could impact The Ensign Group's financial performance.
    • Labor Shortages: The healthcare industry faces a well-documented shortage of qualified caregivers, which could affect The Ensign Group's ability to staff their facilities adequately.
    • Integration Challenges: Their acquisition-driven growth strategy relies on successfully integrating new facilities, and any stumbles in this process could disrupt operations and financial performance.

    Final thoughts on Ensign Group

    The Ensign Group's focus on quality care, their growth strategy, and the high-growth potential of the senior living market paint a promising picture for long-term investors seeking exposure to this essential sector. However, the regulatory environment, dependence on reimbursement rates, labor shortages, and integration challenges necessitate careful consideration. Thorough research on The Ensign Group's acquisition pipeline, their operational efficiency metrics, and a clear understanding of the overall senior living industry trends are crucial before adding them to your portfolio. Remember, sometimes the greatest advancements in senior care come from creating vibrant communities that prioritize well-being. The Ensign Group could be a part of your investment journey in senior living solutions, but be sure to carefully assess the potential roadblocks before investing.

  • Chemed Corp (CHE)

    In the vibrant realm where molecules morph into miracles and ailing bodies surrender to the rhythm of treatment, Chemed Corp. reigns supreme. This healthcare titan isn't just crafting pills and potions; it's orchestrating a therapeutic symphony, wielding compassionate care and specialized services to rewrite the story of human well-being. But can this healthcare hero translate its healing touch into rewarding returns for your portfolio? Let's explore the hidden melodies powering Chemed's rise, alongside the potential side effects to consider before joining this medical odyssey.

    Chemed Corp financial statements

    Analysts recommendation: 1.25

    Financial Health

    • Return on assets (ROA): 17.94%
    • Return on equity (ROE): 27.47%
    • Return on investment (ROI): 21.96%

    Profitability

    • Gross margin: 32.77%
    • Operating margin: 14.83%
    • Net profit margin: 12.36%

    Growth

    • EPS (past 5 years): 7.95%
    • EPS (current): 18.57
    • EPS estimate (next quarter): 5.59
    • EPS growth (this year): 14.33%
    • EPS growth (next year): 8.9%
    • EPS growth (next 5 years): 11.25%
    • EPS growth (quarter-over-quarter): 18.34%
    • Sales growth (past 5 years): 4.95%
    • Sales growth (quarter-over-quarter): 5.19%

    💡 Why invest in Chemed Corp?

    Chemed's leading position in hospice care, Roto-Rooter's plumbing expertise, strategic acquisitions, and consistent dividend payments create a compelling case for investors seeking exposure to the dynamic healthcare sector. Here's what fuels its engine of well-being:

    • Hospice Hero: Chemed boasts VITAS Healthcare, a national leader in end-of-life care, offering comfort and dignity to patients and their families. This leadership in hospice translates to consistent demand and predictable revenue streams, securing a strong foundation for future growth.
    • Plumbing Powerhouse: Beyond hospice, Chemed wields Roto-Rooter, the nation's premier plumbing and drain cleaning service, ensuring essential home repairs and water safety. This diversification mitigates risk and unlocks unique growth avenues in a crucial service sector.
    • Acquisition Alchemist: Chemed actively seeks strategic acquisitions, expanding its service offerings and geographic reach. This growth-oriented approach keeps the company relevant and taps into diverse healthcare needs, further bolstering its future prospects.
    • Dividend Delights: Chemed has a stellar track record of regular dividend payments, rewarding shareholders with a portion of its profits. This steady income stream makes it attractive to investors seeking stability and income within their portfolio.

    🐌 Key considerations before investing in Chemed Corp

    While Chemed navigates the medical maze with its compassionate care and service expertise, there are some potential hurdles to consider before joining this healthcare odyssey:

    • Valuation Concerns: Like many established healthcare companies, CHE's stock currently sits near all-time highs. This might limit immediate gains, and a cautious approach with a patient, long-term perspective might be wise.
    • Regulatory Maze: Evolving healthcare regulations and reimbursement challenges can impact Chemed's profitability and operational efficiency. Close monitoring of regulatory changes and their potential impact is crucial.
    • Competition Conundrum: Healthcare services face competition from diverse providers, requiring Chemed to constantly innovate and refine its offerings to maintain its competitive edge. Stay informed about industry trends and how Chemed plans to differentiate itself.
    • Demographic Dependence: Chemed's hospice services rely on an aging population. Shifts in demographics and healthcare policies can potentially impact demand and profitability. Monitoring long-term demographic trends and Chemed's adaptation strategies is vital.

    Final thoughts on Chemed Corp

    Chemed's hospice leadership, plumbing powerhouse status, acquisition strategy, and consistent dividends paint a potentially promising picture for long-term investors seeking exposure to the resilient and diverse healthcare sector. However, near-peak valuation, regulatory uncertainties, rising competition, and demographic dependence warrant a measured approach. Thorough research, analysis of Chemed's future plans and the healthcare landscape, and a clear understanding of your risk tolerance are crucial before joining this medical journey. Remember, navigating the intricate terrain of healthcare stocks requires both a discerning eye for innovative services and a balanced perspective on potential challenges. Choose wisely, and your portfolio might just tap into the therapeutic harmonies orchestrated by Chemed Corp.

  • Bruker Corporation (BRKR)

    In the intricate realm where atoms whisper secrets and molecules dance to the rhythm of scientific inquiry, Bruker Corporation reigns supreme. This analytical technology titan isn't just crafting microscopes and spectrometers; it's orchestrating a symphony of instruments, unlocking the mysteries of materials, pharmaceuticals, and life itself. But can this scientific alchemist concoct rewarding returns for your portfolio? Let's explore the hidden elements powering Bruker's rise, alongside the potential uncertainties to consider before joining this research odyssey.

    Bruker Corporation financial statements

    Analysts recommendation: 2.18

    Financial Health

    • Return on assets (ROA): 9.71%
    • Return on equity (ROE): 30.94%
    • Return on investment (ROI): 14.05%

    Profitability

    • Gross margin: 50.43%
    • Operating margin: 14.49%
    • Net profit margin: 13.38%

    Growth

    • EPS (past 5 years): 20.48%
    • EPS (current): 2.74
    • EPS estimate (next quarter): 0.52
    • EPS growth (this year): 2.37%
    • EPS growth (next year): 18.16%
    • EPS growth (next 5 years): 12.9%
    • EPS growth (quarter-over-quarter): -32.68%
    • Sales growth (past 5 years): 9.74%
    • Sales growth (quarter-over-quarter): 5.31%

    💡 Why invest in Bruker Corporation?

    Bruker's dominant position in high-resolution instruments, unwavering commitment to innovation, diversified portfolio, and global reach create a compelling case for investors seeking exposure to the scientific frontiers. Here's what fuels its alchemy:

    • Analytical Alchemy Master: Bruker dominates niche markets for high-resolution mass spectrometers, electron microscopes, and other advanced analytical instruments, providing crucial tools for research across diverse scientific disciplines. This leadership translates to strong and predictable revenue streams from academia and industry giants.
    • Innovation Elixir: From AI-powered data analysis to cutting-edge biomolecular imaging, Bruker invests heavily in R&D, constantly pushing the boundaries of analytical frontiers. This commitment to innovation ensures its offerings remain relevant and in-demand, paving the way for future advancements.
    • Diversification Delights: Beyond its core instruments, Bruker expands its reach through software solutions, aftermarket services, and strategic acquisitions, mitigating risk and unlocking diverse growth avenues. This multi-pronged approach creates a resilient portfolio in the dynamic scientific landscape.
    • Global Expansionist: With operations spanning continents, Bruker taps into diverse research needs and unlocks international growth potential. This global reach provides access to emerging markets with burgeoning scientific endeavors, further bolstering its future prospects.

    🐌 Key considerations before investing in Bruker Corporation

    While Bruker shines bright, some potential uncertainties deserve careful consideration before embarking on this research odyssey:

    • Valuation Concerns: Like many established technology companies, BRKR's stock currently sits near all-time highs. This might limit immediate gains, and a cautious approach with a patient, long-term perspective might be wise.
    • R&D Rollercoaster: Success in the scientific instrument space hinges on consistent innovation and successful product launches. While Bruker has a strong track record, R&D failures can impact future performance.
    • Competition Heats Up: Other tech giants and nimble startups are vying for market share, requiring Bruker to constantly innovate and refine its offerings to maintain its competitive edge. Stay informed about competitor advancements and how Bruker plans to stay ahead of the curve.
    • Economic Jitters: Economic downturns can impact research budgets and capital expenditures, potentially decreasing demand for Bruker's high-priced instruments. Monitor broader economic trends to anticipate potential fluctuations in the sector.

    Final thoughts on Bruker Corporation

    Bruker's analytical dominance, unwavering innovation, diversified portfolio, and global reach paint a potentially promising picture for long-term investors seeking exposure to the booming field of scientific research. However, near-peak valuation, R&D uncertainties, rising competition, and economic sensitivities warrant a measured approach. Thorough research, analysis of Bruker's future plans and the scientific landscape, and a clear understanding of your risk tolerance are crucial before joining this analytical adventure. Remember, navigating the intricate terrain of scientific instrument stocks requires both a discerning eye for cutting-edge technologies and a balanced perspective on potential headwinds. Choose wisely, and your portfolio might just unlock the mysteries of the scientific universe powered by the analytical alchemy of Bruker Corporation.